These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
533 related articles for article (PubMed ID: 25935645)
1. Randomized phase III trial of radiotherapy or chemoradiotherapy with topotecan and cisplatin in intermediate-risk cervical cancer patients after radical hysterectomy. Sun W; Wang T; Shi F; Wang J; Wang J; Hui B; Zhang Y; Lu J; Chen H; Liu Z BMC Cancer; 2015 May; 15():353. PubMed ID: 25935645 [TBL] [Abstract][Full Text] [Related]
2. Outcome and toxicity of radical radiotherapy or concurrent Chemoradiotherapy for elderly cervical cancer women. Wang W; Hou X; Yan J; Shen J; Lian X; Sun S; Liu Z; Meng Q; Wang D; Zhao M; Qiu J; Hu K; Zhang F BMC Cancer; 2017 Aug; 17(1):510. PubMed ID: 28764676 [TBL] [Abstract][Full Text] [Related]
3. Concurrent paclitaxel/cisplatin chemoradiotherapy with or without consolidation chemotherapy in high-risk early-stage cervical cancer patients following radical hysterectomy: preliminary results of a phase III randomized study. Zhao H; Li L; Su H; Lin B; Zhang X; Xue S; Fei Z; Zhao L; Pan Q; Jin X; Xie C Oncotarget; 2016 Oct; 7(43):70969-70978. PubMed ID: 27391158 [TBL] [Abstract][Full Text] [Related]
4. Adjuvant chemotherapy versus concurrent chemoradiotherapy for high-risk cervical cancer after radical hysterectomy and systematic lymphadenectomy. Takekuma M; Kasamatsu Y; Kado N; Kuji S; Tanaka A; Takahashi N; Abe M; Hirashima Y Int J Clin Oncol; 2016 Aug; 21(4):741-747. PubMed ID: 26857458 [TBL] [Abstract][Full Text] [Related]
5. 20 year experience of postoperative radiotherapy in IB-IIA cervical cancer patients with intermediate risk factors: impact of treatment period and concurrent chemotherapy. Song S; Song C; Kim HJ; Wu HG; Kim JH; Park NH; Song YS; Kim JW; Kang SB; Ha SW Gynecol Oncol; 2012 Jan; 124(1):63-7. PubMed ID: 22004904 [TBL] [Abstract][Full Text] [Related]
6. Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients. Mabuchi S; Isohashi F; Okazawa M; Kitada F; Maruoka S; Ogawa K; Kimura T J Gynecol Oncol; 2017 Jan; 28(1):e15. PubMed ID: 27958682 [TBL] [Abstract][Full Text] [Related]
7. Analysis of the effect of adjuvant radiotherapy on outcomes and complications after radical hysterectomy in FIGO stage IB1 cervical cancer patients with intermediate risk factors (GOTIC Study). Nakamura K; Kitahara Y; Satoh T; Takei Y; Takano M; Nagao S; Sekiguchi I; Suzuki M World J Surg Oncol; 2016 Jun; 14(1):173. PubMed ID: 27356862 [TBL] [Abstract][Full Text] [Related]
8. A phase II study of postoperative concurrent carboplatin and paclitaxel combined with intensity-modulated pelvic radiotherapy followed by consolidation chemotherapy in surgically treated cervical cancer patients with positive pelvic lymph nodes. Mabuchi S; Isohashi F; Yokoi T; Takemura M; Yoshino K; Shiki Y; Ito K; Enomoto T; Ogawa K; Kimura T Gynecol Oncol; 2016 May; 141(2):240-246. PubMed ID: 26883141 [TBL] [Abstract][Full Text] [Related]
9. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. Long HJ; Bundy BN; Grendys EC; Benda JA; McMeekin DS; Sorosky J; Miller DS; Eaton LA; Fiorica JV; J Clin Oncol; 2005 Jul; 23(21):4626-33. PubMed ID: 15911865 [TBL] [Abstract][Full Text] [Related]
11. Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04. Ahn JS; Ahn YC; Kim JH; Lee CG; Cho EK; Lee KC; Chen M; Kim DW; Kim HK; Min YJ; Kang JH; Choi JH; Kim SW; Zhu G; Wu YL; Kim SR; Lee KH; Song HS; Choi YL; Sun JM; Jung SH; Ahn MJ; Park K J Clin Oncol; 2015 Aug; 33(24):2660-6. PubMed ID: 26150444 [TBL] [Abstract][Full Text] [Related]
12. [Curative effect analysis of postoperative concurrent chemoradiotherapy on early-stage cervical cancer patients with intermediate-risk factors]. Tang Q; Tu YQ; Chen JH; Lyu XJ; Yan DD Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):462-466. PubMed ID: 29936774 [No Abstract] [Full Text] [Related]
13. Postoperative adjuvant concurrent chemoradiotherapy improves survival rates for high-risk, early stage cervical cancer patients. Ryu HS; Chun M; Chang KH; Chang HJ; Lee JP Gynecol Oncol; 2005 Feb; 96(2):490-5. PubMed ID: 15661240 [TBL] [Abstract][Full Text] [Related]
14. [Concurrent chemoradiotherapy followed by consolidation chemotherapy and sequential chemoradiotherapy for stage III non-small cell lung cancer: comparison in 93 patients]. Sun WZ; Song LP; Zhang YB; Ai T; Lu JL; Ren J; Gao Y Nan Fang Yi Ke Da Xue Xue Bao; 2012 Mar; 32(3):362-7. PubMed ID: 22445984 [TBL] [Abstract][Full Text] [Related]
15. [Concurrent chemoradiotherapy versus radiotherapy in advanced cervical carcinoma]. Zeng SY; Li LY; Shu KY; Pan M; Li HP; Luo B Ai Zheng; 2008 Sep; 27(9):942-6. PubMed ID: 18799032 [TBL] [Abstract][Full Text] [Related]
16. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. Lefebvre JL; Pointreau Y; Rolland F; Alfonsi M; Baudoux A; Sire C; de Raucourt D; Malard O; Degardin M; Tuchais C; Blot E; Rives M; Reyt E; Tourani JM; Geoffrois L; Peyrade F; Guichard F; Chevalier D; Babin E; Lang P; Janot F; Calais G; Garaud P; Bardet E J Clin Oncol; 2013 Mar; 31(7):853-9. PubMed ID: 23341517 [TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy of nedaplatin-based concurrent chemoradiotherapy for uterine cervical cancer: a Tohoku Gynecologic Cancer Unit Study. Kagabu M; Shoji T; Murakami K; Omi H; Honda T; Miura F; Yokoyama Y; Tokunaga H; Takano T; Ohta T; Shimizu D; Sato N; Soeda S; Watanabe T; Yamada H; Mizunuma H; Yaegashi N; Nagase S; Tase T; Sugiyama T Int J Clin Oncol; 2016 Aug; 21(4):735-740. PubMed ID: 26782958 [TBL] [Abstract][Full Text] [Related]
18. Adjuvant intensity-modulated radiotherapy (IMRT) with concurrent paclitaxel and cisplatin in cervical cancer patients with high risk factors: A phase II trial. Wang X; Shen Y; Zhao Y; Li Z; Gou H; Cao D; Yang Y; Qiu M; Li Q; Liu J; Yi C; Liao Z; Luo D; Xu F; Bi F Eur J Surg Oncol; 2015 Aug; 41(8):1082-8. PubMed ID: 26033265 [TBL] [Abstract][Full Text] [Related]